Zynerba stock rises as CBD gel improves rare disorder symptoms; autism program deferred
Zynerba Pharmaceuticals (ZYNE) stock rose ~8% premarket June 22 after the company said its transdermal CBD gel Zygel help improve behavior symptoms of 22q11.2 Deletion Syndrome in...